Top Page
Global Health Limited
(MEDANTA)
Global Health Limited (MEDANTA) vs. iShares MSCI India ETF (INDA)
Global Health Limited Business Overview & Revenue Model
Global Health Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 38.62B | 36.92B | 32.75B | 26.94B | 21.67B | 14.29B |
| Gross Profit | 27.48B | 19.88B | 17.17B | 20.69B | 16.24B | 10.81B |
| EBITDA | 9.91B | 8.77B | 8.72B | 6.78B | 4.90B | 2.23B |
| Net Income | 5.34B | 4.81B | 4.78B | 3.26B | 1.96B | 288.05M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 47.66B | 43.04B | 41.16B | 31.46B | 26.94B |
| Cash, Cash Equivalents and Short-Term Investments | 11.22B | 10.51B | 11.56B | 12.60B | 5.12B | 2.89B |
| Total Debt | 0.00 | 7.18B | 8.02B | 11.22B | 11.09B | 9.31B |
| Total Liabilities | -33.88B | 13.79B | 13.98B | 16.88B | 15.30B | 13.12B |
| Stockholders Equity | 33.88B | 33.86B | 29.06B | 24.28B | 16.16B | 13.82B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 1.07B | 3.33B | 4.09B | 367.87M | 960.32M |
| Operating Cash Flow | 0.00 | 6.24B | 6.12B | 6.45B | 3.11B | 2.42B |
| Investing Cash Flow | 0.00 | -7.21B | -4.41B | -3.42B | -4.21B | -2.39B |
| Financing Cash Flow | 0.00 | -972.26M | -5.14B | 3.46B | 1.60B | -807.23M |
Global Health Limited Technical Analysis
Global Health Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₹399.91B | 47.09 | ― | 0.23% | 14.72% | 8.37% | |
65 Neutral | ₹335.69B | 62.80 | ― | 0.04% | 15.78% | 15.01% | |
65 Neutral | ₹287.00B | 76.23 | ― | ― | 25.74% | 1.41% | |
62 Neutral | ₹356.83B | 108.59 | ― | 0.76% | -36.14% | -93.99% | |
61 Neutral | ₹769.00B | 88.54 | ― | 0.11% | 15.33% | 54.62% | |
61 Neutral | ₹105.27B | 68.82 | ― | 0.21% | 15.41% | 5.93% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Global Health Limited Corporate Events
Global Health Limited has announced a schedule of meetings with investors and analysts, including firms like Morgan Stanley and UTI, to be held in November 2025. These meetings, which will take place in Noida and Mumbai, are intended to engage with stakeholders without sharing any unpublished price-sensitive information, indicating a proactive approach to investor relations and transparency.
Global Health Limited has announced a schedule of meetings with investors and analysts, which will take place in November 2025. These meetings, involving firms such as Morgan Stanley and UTI, will be conducted in person in Noida and Mumbai. The company emphasized that no unpublished price-sensitive information will be disclosed during these interactions, indicating a focus on maintaining transparency and regulatory compliance.
Global Health Limited has announced a series of meetings with investors and analysts scheduled for mid-November 2025. These meetings, which will take place in person in Noida and Mumbai, are part of the company’s ongoing efforts to engage with stakeholders and provide updates on its operations, although no unpublished price-sensitive information will be disclosed. This initiative reflects the company’s commitment to transparency and maintaining strong relationships with its investors and analysts, which could positively impact its market positioning.
Global Health Limited has announced a schedule of meetings with investors and analysts, which will take place in mid-November 2025. These meetings, including one-on-one and group sessions, are set to occur in Noida and Mumbai, providing an opportunity for the company to engage with key stakeholders and discuss its strategic initiatives. The company has clarified that no unpublished price-sensitive information will be shared during these meetings, ensuring compliance with regulatory requirements.
Global Health Limited has announced an upcoming Earnings Conference Call scheduled for November 10, 2025, to discuss the financial results for the second quarter and half-year ending September 30, 2025. This call, hosted by IIFL Capital, will feature key management figures and is a critical event for stakeholders to gain insights into the company’s financial performance and strategic direction.
Global Health Limited has announced that it has secured a 3.5-acre land allotment from Assam Industrial Development Corporation Limited for the construction of a new hospital in Guwahati, Assam. This development marks a significant step in the company’s expansion strategy, as it plans to initiate construction activities in phases, potentially enhancing its market positioning and service reach in the northeastern region of India.
Global Health Limited has received an in-principle approval from the Assam Industrial Development Corporation Limited for the allotment of 3.5 acres of land in Guwahati, Assam, to establish a new hospital. This strategic move is part of the company’s expansion efforts to increase its healthcare footprint in the region, potentially enhancing its market position and offering improved healthcare services to the local population.
Global Health Limited has announced the details of its 21st Annual General Meeting, which is scheduled to take place on September 19, 2025, via video conferencing. This move aligns with regulatory compliance and ensures shareholder engagement despite potential physical meeting constraints, reflecting the company’s adaptability and commitment to transparent communication with its stakeholders.
Global Health Limited has released the transcript of its Earnings Conference Call for the first quarter of the fiscal year 2026, which ended on June 30, 2025. The disclosure, made in compliance with SEBI regulations, is aimed at providing transparency and insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder relations.